168 related articles for article (PubMed ID: 27699032)
61. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Dai X; Zhang X; Wang C; Jiang J; Wu C
Oncotarget; 2017 May; 8(18):30495-30501. PubMed ID: 27911869
[TBL] [Abstract][Full Text] [Related]
62. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
63. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
64. Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
Affronti ML; Jackman JG; McSherry F; Herndon JE; Massey EC; Lipp E; Desjardins A; Friedman HS; Vlahovic G; Vredenburgh J; Peters KB
Oncologist; 2018 Aug; 23(8):889-e98. PubMed ID: 29666296
[TBL] [Abstract][Full Text] [Related]
65. Efficacy of FOLFOXIRI versus XELOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer.
Cheng Y; Song W
Int J Clin Exp Med; 2015; 8(10):18713-20. PubMed ID: 26770486
[TBL] [Abstract][Full Text] [Related]
66. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Aparicio T; Bouché O; Taieb J; Maillard E; Kirscher S; Etienne PL; Faroux R; Khemissa Akouz F; El Hajbi F; Locher C; Rinaldi Y; Lecomte T; Lavau-Denes S; Baconnier M; Oden-Gangloff A; Genet D; Paillaud E; Retornaz F; François E; Bedenne L;
Ann Oncol; 2018 Jan; 29(1):133-138. PubMed ID: 29045659
[TBL] [Abstract][Full Text] [Related]
67. [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Sato A; Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Koizumi W; Mizunuma N; Takiuchi H
Gan To Kagaku Ryoho; 2011 Apr; 38(4):561-9. PubMed ID: 21498982
[TBL] [Abstract][Full Text] [Related]
68. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
69. [Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
Hong L; Guo Z; Yu H; Li B; Si T; Liu C
Zhonghua Yi Xue Za Zhi; 2014 Jul; 94(25):1929-32. PubMed ID: 25253003
[TBL] [Abstract][Full Text] [Related]
70. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Komatsu Y; Yuki S; Sogabe S; Fukushima H; Nakatsumi H; Kobayashi Y; Iwanaga I; Nakamura M; Hatanaka K; Miyagishima T; Kudo M; Munakata M; Meguro T; Tateyama M; Sakata Y
Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343
[TBL] [Abstract][Full Text] [Related]
71. Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
Tate S; Nishikimi K; Matsuoka A; Otsuka S; Shiko Y; Ozawa Y; Kawasaki Y; Shozu M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202220
[TBL] [Abstract][Full Text] [Related]
72. Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer.
Li Z; Hou X; Chen J; Sun H; Mi Y; Sui Y; Li Y; Xie J; Qiao Y; Lei X; Che X; Liu J
Oncol Lett; 2017 Jul; 14(1):579-586. PubMed ID: 28693208
[TBL] [Abstract][Full Text] [Related]
73. Curative effect of bevacizumab combined with chemotherapy in advanced or recurrent uterine sarcoma.
Han Y; Li S; Holt HK; Wu L
Mol Clin Oncol; 2016 Feb; 4(2):245-248. PubMed ID: 26893869
[TBL] [Abstract][Full Text] [Related]
74. Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab
Balaña C; Estival A; Pineda E; Sepúlveda J; Mesía C; Del Barco S; Gil-Gil M; Hardy M; Indacoechea A; Cardona AF
Neurooncol Pract; 2017 Mar; 4(1):15-23. PubMed ID: 31385992
[TBL] [Abstract][Full Text] [Related]
75. Complete remission of peritoneal dissemination of colon cancer by alternate-day S-1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate-day S-1 plus bevacizumab: A case report.
Nitori N; Kato A; Deguchi T; Nakadai J; Tada A; Takahashi M; Umeda R; Miyata N; Kataoka M; Kadomura T; Higuchi H; Ebinuma H; Kato A; Hatori T; Ikeda Y; Miyazaki M
Mol Clin Oncol; 2019 Feb; 10(2):270-274. PubMed ID: 30680207
[TBL] [Abstract][Full Text] [Related]
76. Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study.
Isono-Taniguchi R; Goto M; Takimoto Y; Ueda T; Wakimoto Y; Inoue K; Hori K; Ito K; Tsubamoto H
Gynecol Oncol Rep; 2022 Aug; 42():101013. PubMed ID: 36118995
[TBL] [Abstract][Full Text] [Related]
77. A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study).
Nagasawa T; Shoji T; Takatori E; Kaido Y; Kagabu M; Shimizu D; Shigeto T; Baba T; Sugiyama T; Yokoyama Y
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958375
[TBL] [Abstract][Full Text] [Related]
78. Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases.
Isono-Nakata R; Tsubamoto H; Ueda T; Inoue K; Shibahara H
Gynecol Oncol Rep; 2018 May; 24():57-60. PubMed ID: 29682600
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.
Yang L; Yang Y; Qin Q; Zhou A; Zhao J; Wang J; Shu C; Yuan X; Hu S
Oncol Lett; 2015 Mar; 9(3):1451-1457. PubMed ID: 25663930
[TBL] [Abstract][Full Text] [Related]
80. Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.
Laskey RA; Richard SD; Smith AL; Lin JF; Beck TL; Lesnock JL; Kelley JL; Olawaiye AB; Sukumvanich P; Krivak TC
Onco Targets Ther; 2014; 7():469-76. PubMed ID: 24711703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
